Helixgate

Helixgate

Uncategorized

Pathogenic Bacterium Rewires Gut Environment to Colonize and Cause Disease

Published

on

An international research team headed by scientists at Vanderbilt University Medical Center has shown how an intestinal pathogen reshapes the gut environment to fuel its own colonization and cause disease. The team’s studies found that enterotoxigenic Bacteroides fragilis (ETBF) uses a toxin it produces, Bacteroides fragilis toxin (BTF), to reprogram intestinal cell metabolism and generate conditions that support its growth. ETBF is a classically anaerobic bacterium that causes diarrhea and has been implicated in inflammatory diseases, including colitis and colorectal cancer. The study findings point to potential new therapeutic strategies for disrupting the growth of pathogens such as ETBF.

“Our findings suggest that disease-associated microbes don’t just respond to inflammation—they can actively drive it by reshaping host metabolism,” stated Wenhan Zhu, PhD, assistant professor of pathology, microbiology and immunology. “This opens up new possibilities for intervention, such as by targeting metabolic interactions between host and microbes to prevent or disrupt diseases like infectious diarrhea and colorectal cancer.

Zhu is lead corresponding author of the team’s published paper in Cell, titled “An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut.” In their paper the team wrote, “Here, we demonstrate that ETBF leverages its virulence factor, BFT, to reprogram epithelial cell metabolism, thereby reshaping the gut nutritional landscape. This reprogramming leads to increased levels of lactate and oxygen, which fuel ETBF’s unique oxidative metabolism.”

Independent studies have implicated ETBF in both inflammatory diarrheal diseases and in colorectal cancer, the authors noted. “These pathogenic effects are primarily driven by the virulence factor Bacteroides fragilis toxin (BFT), which elicits a range of physiological alterations in host cells.” However, the team noted, “… the specific mechanisms by which BFT facilitates ETBF niche establishment and promotes persistent colonization in the gut remain largely undefined.”

Zhu has long been interested in how pathogens succeed in the competitive intestinal environment. “The gut is one of the most densely populated microbial environments in the body, with heavy competition for nutrients, yet certain microbes can still take hold and drive disease,” he said. “These microbes are ultimately competing for nutrients, and processes like inflammation and cancer may be ways they alter the environment to gain access to those resources.”

Though the percentage of people who carry ETBF varies from study to study, it can be a common member of the gut microbiota and is considered a classical anaerobe, a type of bacteria that requires low-oxygen conditions (such as those in the large intestine) to survive. It produces a toxin, BFT, that interacts with intestinal host cells, causing inflammation and increasing oxygen and oxidative stress—conditions that are usually harmful to anaerobes such as ETBF.

Zhu and colleagues are exploring how ETBF navigates and exploits these conditions, to gain insight into microbial physiology and host-microbe interactions, he said. Through their newly reported study the investigators found that ETBF uses its toxin, BFT, to reprogram intestinal epithelial cell metabolism.

The researchers discovered that ETBF reshapes the intestinal landscape in unexpected ways, for example by driving epithelial cell proliferation and manipulating immune signaling pathways and bile acid biology. “BFT manipulates colonic epithelial signaling and the bile acid recycling pathway, inducing a metabolic shift in the epithelium from oxidative phosphorylation to glycolysis,” they wrote.

This metabolic shift reduces oxygen consumption by host cells, increasing oxygen availability in the gut. The resulting environment supports the growth of ETBF, despite it being traditionally considered an anaerobe. “This shift increases local concentrations of lactate and oxygen, nutrients that support oxidative metabolism in ETBF,” they continued. These changes also create conditions that promote disease-associated microbial communities linked to colorectal cancer.

“One of our most surprising findings was that a classically anaerobic bacterium can benefit from, and even help create, an oxygen-rich environment,” Zhu said. “This challenges the traditional view that anaerobic microbes simply cannot tolerate oxygen.”

The team is continuing to explore how ETBF modifies its environment to successfully colonize and cause disease; how broadly the mechanisms apply across other microbes and disease settings; and whether these interactions can be therapeutically targeted. In their report the investigators stated, “… by sculpting an oxidative niche, ETBF both fuels its own growth and suppresses its microbial competitors. Importantly, this distinct metabolic program could potentially be leveraged to selectively target and remove ETBF.” Zhu added, “Ultimately, we hope to identify strategies to disrupt these disease-promoting niches before they lead to long-term pathology.”

The post Pathogenic Bacterium Rewires Gut Environment to Colonize and Cause Disease appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

AI Predicts Gene Regulation for Drug Discovery Using Condensate Morphology

AI Predicts Gene Regulation for Drug Discovery Using Condensate Morphology

Published

on

In a study published in Cell titled, “Deep learning of functional perturbations from condensate morphology,” researchers at Princeton University have applied AI to understand how drugs affect the dynamics of key structures within the cell. The work introduces a tool that can map morphology to functional outcomes and shed light on markers of health. 

The authors examined the changes in shape of biomolecular condensates, tiny droplets in cells that drive transcription and other gene regulation processes linked to disease, including Alzheimer’s, ALS and cancer. The findings support a robust system for monitoring and evaluating cellular responses to drugs at a single-cell level. 

“The central problem in biology is how do you get emergent structure from individual molecular interactions,” said Cliff Brangwynne, PhD, professor of chemical and biological engineering at Princeton and corresponding author of the study. “The key innovation here was to develop a way to learn from the images and classify the patterns that are emergent.” 

The team used an advanced microscope to image nucleolar morphology changes in hundreds of human cells under a range of drug-controlled conditions. Machine learning tools sorted the images into four basic categories based on the shape of the nucleolus, uncovering “cap” and “necklace” shapes linked to cellular stress responses.

The authors ran a panel of drugs to examine the effect on nucleolar formation and measured changes in the condensate’s development. Varying concentrations caused different degrees of change in both caps and necklaces.  

Two known anti-cancer drugs caused caps, while a third drug, called topotecan, triggered a new nucleolus morphology that the researchers labeled “flower.” While topotecan inhibits TOP1, an key enzyme during DNA replication, loss of TOP1 induced the flower shape and uncovered the enzyme’s role in maintaining nucleolar organization by regulating RNA processing. 

“No one’s seen this flower morphology before,” said Brangwynne. “The network flagged it as not fitting neatly into the other three categories.” 

The team also tested their neural network on other condensates related to RNA processes, observing similar dose-and-response results for drugs specific to nuclear speckles, a hub for messenger RNA activity, and condensates from respiratory syncytial virus. 

This finding underscores the value of analyzing morphological changes. “You could be missing other important features,” said Anita Donlic, PhD, postdoctoral researcher and first author of the study. “Things that could tell you there’s new biology.” 

The post AI Predicts Gene Regulation for Drug Discovery Using Condensate Morphology appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3

Published

on

Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.

Continue Reading

Uncategorized

STAT+: Lilly’s Ajax acquisition may have been worth it

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.

Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.

Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending